Dr. Reed brings impressive record of leadership, teaching, research and clinical careContinue reading
Results of the Triplet Clinical Trial at HonorHealth Research Institute based on the TGen Triple research presented at ASCO-GI symposium in San FranciscoContinue reading
On on April 23, 2017, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.Continue reading
Mayo Clinic and Arizona State University Alliance for Health Care has chosen eight Alliance Fellows to be part of the inaugural Faculty in Residence program.Continue reading
Paradigm Diagnostics announces the launch and IRB approval of the Paradigm registry to allow physicians to better collect, share, and visualize data to help advance personalized medicine in oncology.
Tucson, AZ, April 12, 2017 Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis. This antibody has been validated for use in a dual stain with the VENTANA Basal Cell Cocktail (34ßE12+p63) to aid in distinguishing morphologically difficult cases as benign, atypical or cancerous on a single slide. The assay is an in vitro diagnostic (IVD) primary antibody for use on the VENTANA BenchMark IHC/ISH series of automated slide stainers.Continue reading
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a master services agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for work to be performed in HTG’s VERI/O laboratory. The initial project includes the development of a custom assay for the detection of nearly 3,000 mRNA targets using the HTG EdgeSeq technology.Continue reading